APP下载

人参皂苷Rg3对表达多耐药基因的晚期胃癌患者生存期的影响

2014-09-17王沛陈国荣

中国社区医师 2014年15期
关键词:耐药胃癌

王沛+陈国荣

doi:10.3969/j.issn.1007-614x.2014.15.5

摘 要 目的:观察人参皂苷Rg3对表达胎盘型谷胱甘肽-S-转移酶π(Glutathione-s-transferase π,GST-π)、P-糖蛋白(P-glycoprotein,P-gP)、拓扑异构酶Ⅱ(Topoisomerase Ⅱ,Topo-Ⅱ)等多耐药基因的晚期胃癌患者生存期的影响。方法:利用免疫组织化学技术检测晚期胃癌组织中GST-π、P-gP、Topo-Ⅱ蛋白的表达情况,选取48例初治胃癌组织中≥2个耐药基因蛋白表达阳性患者纳入试验,随机分为治疗组(25人)和对照组(23人),治疗组给予人参皂苷Rg3+奥沙利铂+替吉奥方案为主的化疗,对照组给予奥沙利铂+替吉奥方案为主的化疗,比较两组间生存期的差别。结果:治疗组的中位生存时间(23.000±1.655)个月,对照组的中位生存时间(13.000±1.497)个月,两组间生存期比较差异有统计学意义(P<0.01)。结论:人参皂苷Rg3能较明显地延长有多耐药基因表达的晚期胃癌患者生存期,可能具有逆转晚期胃癌铂类化疗药物耐药的能力。

关键词 胃癌 人参皂苷Rg3 化疗 耐药

Effect of ginsenoside Rg3 on the survival time of advanced gastric cancer patients with expressing multiple drug resistance genes

Wang Pei1,2,Chen Guorong1

Xinxiang Medical University(Xinxiang City,Henan)4530031

The People's Hospital of Linying County,Henan 4626002

Abstract Objective:To observe the effect of ginsenoside Rg3 on the lifetime of advanced gastric cancer patients with expressing multiple drug resistance genes,such as placenta type of glutathione-s-transferaseπ(GST-π),P-glycoprotein(P-gP),topoisomerase Ⅱ(Topo-Ⅱ) and so on.Methods:The expression of GST-π,P-gP,Topo-Ⅱ protein in the advanced gastric cancer tissue were detected by immunohistochemistry.48 cases with 2 or more than 2 expressing positive resistance gene proteins in the early gastric cancer tissue were selected.They were randomly divided into the treatment group(25 cases) and the control group(23 cases).The treatment group were treated with ginsenoside Rg3,oxaliplatin and gimeraciland oteracil porassium chemotherapy.The control group were treated with oxaliplatin and gimeraciland oteracil porassium chemotherapy.The difference of the survival time between the two groups was compared.Results:The median survival time of the treatment group was 23.000±1.655 months.The median survival time of the control group was 13.000±1.497 months. The difference of the survival time between the two groups was statistically significant(P<0.01).Conclusion:Ginsenoside Rg3 can significantly prolong the survival time of advanced gastric cancer patients with expressing multiple drug resistance genes,and maybe reverse platinum chemotherapy drug resistance of advanced gastric cancer.

Key words Gastric cancer;Ginsenoside Rg3;Chemotherapy;Drug resistance

目前胃癌的化疗方案虽然在不断完善,但由于肿瘤对药物的敏感性不同,在不同患者中的相同肿瘤对抗癌药物的敏感性也不相同,甚至同一患者的不同阶段对药物的敏感性也存在差异,所以在术后的辅助治疗中,化疗的疗效不佳。其中化疗失败的根本原因是多药耐药(Multidrug resistance,MDR)。MDR是指肿瘤细胞不仅对一种抗肿瘤药物产生耐药,而且对不同的作用机制和化学结构,甚至未在化疗中使用的其他抗肿瘤药物产生交叉、广谱耐药的现象[1~3]。奥沙利铂(Oxaliplatin)是继顺铂、卡铂之后的第3代铂类抗癌药,已逐渐作为治疗中晚期胃癌的主要药物,但一些患者对奥沙利铂产生耐药,严重影响了化疗效果,即出现多药耐药(MDR)现象。……

登录APP查看全文

猜你喜欢

耐药胃癌
如何判断靶向治疗耐药
Ibalizumab治疗成人多耐药HIV-1感染的研究进展
miR-181a在卵巢癌细胞中对顺铂的耐药作用
超级耐药菌威胁全球,到底是谁惹的祸?
胃癌组织中PGRN和Ki-67免疫反应性增强
P53及Ki67在胃癌中的表达及其临床意义
胃癌组织中Her-2、VEGF-C的表达及意义
胃癌组织中LKB1和VEGF-C的表达及其意义
胃癌组织中VEGF和ILK的表达及意义
PDCA循环法在多重耐药菌感染监控中的应用